Jubilant Pharmova Limited

BSE: 530019 NSE: JUBLPHARMA
Jubilant Pharmova Limited - pharma in Uttar Pradesh, India. FY 2026 financials & compliance.
CIN L24116UP1978PLC004624 Incorporated 21 June 1978 ROC Uttar Pradesh HQ Uttar Pradesh, India
Active Listed - NSE: JUBLPHARMA · BSE: 530019 Public Limited Company pharma Fortune India 500 · #334 BSE 500
Data last updated
Market Cap
₹14,805 Cr
JUBLPHARMA · NSE
Share Price
₹932.20
+0.30% today
Revenue
₹8,280 Cr
FY 2025-26 · +14.5% YoY
EBITDA
₹1,200 Cr
Margin 14.5%
Net Profit
₹436 Cr
FY 2025-26 · +9.1% YoY
P/E (TTM)
38.4x
P/B 2.1x
ROE
6.0%
ROCE 6.9%
Debt / Equity
0.48
Interest cover 27.9x

About Jubilant Pharmova Limited

Data last updated:

Jubilant Pharmova Limited is a public limited company based in Uttar Pradesh, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 21 June 1978 and has been in existence for over 48 years.

Jubilant Pharmova is ranked #334 on the Fortune India 500 (2025). It is part of the BSE 500 index. Its director Shyam Bhartia is #251 among India's richest people (2026). Its director Hari Bhartia is #252 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Uttar Pradesh, under CIN L24116UP1978PLC004624. Its GSTIN is 09AABCV0200H1ZU (Uttar Pradesh). The company holds 36 GST registrations, of which 4 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 530019 and NSE: JUBLPHARMA.

The company has an authorised share capital of ₹143.02 Cr and a paid-up capital of ₹15.93 Cr. It was formerly known as Vam Organic Chemicals Limited and Jubilant Organosys Limited. It is led by directors including Priyavrat Bhartia (Managing Director) and Arjun Shanker Bhartia (Managing Director).

Its last annual general meeting (AGM) was held on 29 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Bhartiagram Gajraulajyotiba Phoolay Nagar, Uttar Pradesh, India – 244223.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹8,279.6 Cr, a growth of 14.4% compared to the previous year. For the same year it recorded a net profit of ₹435.88 Cr (net margin 5.3%) and EBITDA of ₹1,200.3 Cr (EBITDA margin 14.5%). The net worth stands at ₹7,092.8 Cr (up 13.4% YoY). Total assets are valued at ₹13,048 Cr (up 21.2% YoY).

The company has about 1,055 employees on its provident fund (EPFO) records. Its group structure includes 7 subsidiaries.

The company is associated with 3 brands: Jubilant Biosys, Jubilant Life Sciences and Jubilant Pharmova. As per MCA filings, the company has open charges of ₹260 Cr and satisfied charges of ₹9,285.57 Cr on record. Court records list 330 cases involving the company, including 191 filed by the company and 140 filed against it; 58 cases are pending. The company has 72 deals on record (47 market trades, 17 secondary share transfers, 8 funding rounds), with disclosed funding of ₹498.8 Cr; the latest was in June 2025. The company has 9 MSME Form 1 returns on record between 2022 and 2024, listing 2,102 overdue payments to 260 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website jubilantpharmova.com.

Company details

CIN L24116UP1978PLC004624
Registration Number 004624
Incorporation Date 21 June 1978
ROC Uttar Pradesh
Listing Status Listed - Listed on NSE (JUBLPHARMA); Listed on BSE (530019)
Company Status Active
Date of Last AGM 29 August 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Jubilant Pharmova has undergone 3 name changes throughout its history. The company was previously known as Vam Organic Chemicals Limited, Jubilant Organosys Limited, and Jubilant Life Sciences Limited. The current legal name is Jubilant Pharmova Limited.

Company NameStatus
Jubilant Pharmova LimitedCurrent
Vam Organic Chemicals LimitedPrevious
Jubilant Organosys LimitedPrevious
Jubilant Life Sciences LimitedPrevious

CIN history

Jubilant Pharmova has one previous CIN (Corporate Identification Number): U24116UP1978PLC004624. The current CIN is L24116UP1978PLC004624, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24116UP1978PLC004624Current
U24116UP1978PLC004624Previous
Key People
Priyavrat Bhartia Managing Director Arjun Shanker Bhartia Managing Director Arun Seth Director

Recognitions & Rankings of Jubilant Pharmova

Fortune India 500 2025 edition
Rank#334
Total income
₹7,616 Cr
Profit
₹839 Cr
Last year #331
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#299
Valuation
₹18,570 Cr
2021 #332
India's Richest People 2026 edition · 2 directors · Source: Hurun India
Stock market indices
BSE 500

Contact details

Jubilant Pharmova Limited's registered office is in Uttar Pradesh. Its website is jubilantpharmova.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    jubilantpharmova.com
  • Social Media
  • Registered Address
    Bhartiagram Gajraulajyotiba Phoolay Nagar, Uttar Pradesh, India – 244223
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Jubilant Pharmova Limited, buy the company report.

Comprehensive company report
Jubilant Pharmova Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Jubilant Pharmova operates multiple associated brands including Jubilant Biosys, Jubilant Life Sciences, and Jubilant Pharmova. Each brand links to its own profile.

BrandDescriptionWebsite
Jubilant Biosys
Offers integrated drug discovery, research, and manufacturing for pharmaceuticals.jubilantbiosys.com
Jubilant Life Sciences
Company offering a suite of R&D and manufacturing services for small molecules and genericsjubl.com
Jubilant Pharmova
CDMO focused on manufacturing of solid, semi solid, liquid, and injectible drug formulationsjubilantpharmova.com

Business activity

The main business activities of Jubilant Pharmova are professional, scientific and technical and manufacturing. In detail, this covers management consultancy activities and chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products. 2 activity segments are registered with the MCA.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
MProfessional, Scientific and TechnicalM3Management consultancy activities
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Jubilant Pharmova Limited, buy the company report.

Financials of Jubilant Pharmova Limited

FY 2025-26 filings available

Jubilant Pharmova Limited reported revenue of ₹8,279.6 Cr (up 14.4% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹8,280 Cr
+14.4% YoY
EBITDA
₹1,200 Cr
+2.3% YoY
Profit After Tax
₹436 Cr
+9.1% YoY
Net Worth
₹7,093 Cr
+13.4% YoY
Total Assets
₹13,048 Cr
+21.2% YoY
Total Debt
₹3,615 Cr
+32.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue8,2807,2346,7036,2826,1306,0995,976
Revenue growth+14.5%+7.9%+6.7%+2.5%+0.5%+2.1%-
EBITDA1,2001,1737327191,1461,3751,515
EBITDA margin+14.5%+16.2%+10.9%+11.5%+18.7%+22.6%+25.4%
Profit before tax61498117027.806301,1331,233
Net profit43640045.30(389)416856922
Net profit margin+5.3%+5.5%+0.7%-6.2%+6.8%+14.0%+15.4%
EPS (₹)25.2253.134.88(3.84)26.0052.5156.39
Balance sheet
Total assets13,04810,7629,7489,4318,6127,69210,572
Net worth7,0936,2555,4345,3995,3194,7415,604
Total debt3,6152,7313,6643,6773,1922,8304,808
Cash & bank1,2681,0899571,0149846711,400
Net working capital1,8851,7552,2862,3432,4331,9743,352
Cash flow
Cash from operations1,2271,0729716618381,7841,543
Cash from investing(1,143)512(596)(474)(323)(727)(267)
Cash from financing94.90(1,453)(432)(157)(32.60)(1,709)(1,050)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2292,2902,1221,9661,9011,9291,8221,752
Revenue growth (YoY)+17.3%+18.7%+16.5%+12.2%+9.8%---
Other income19.9023.7020.509.8012.0011.909.2021.70
EBITDA248326250336290342268275
EBITDA margin+11.2%+14.3%+11.8%+17.1%+15.4%+17.9%+14.8%+15.8%
Depreciation12711712110598.1095.2091.3091.40
Interest54.2056.5056.1050.2049.0052.7055.6061.00
Profit before tax86.4017693.40190154206130144
Tax30.0056.7037.6070.4051.9054.7029.8041.90
Net profit56.4011955.80120102151101102
EPS (₹)3.567.523.527.576.479.686.366.46
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2642317858107262,7103,140
Revenue growth+13.9%-70.5%-3.1%+11.6%-73.2%-13.7%-
EBITDA40.1037.7016.503.106.46427369
EBITDA margin+15.2%+16.3%+2.1%+0.4%+0.9%+15.8%+11.8%
Profit before tax72.5038.4041.7079.3084.72273299
Net profit70.8422.2032.3649.6580.47215326
Net profit margin+26.9%+9.6%+4.1%+6.1%+11.1%+7.9%+10.4%
EPS (₹)3.971.211.993.145.0513.4620.16
Balance sheet
Total assets2,3772,6822,7822,7842,6461,7914,687
Net worth2,3122,3182,3742,4142,4391,2822,607
Total debt52.703363803461835042,013
Cash & bank10.3012.6036.1011.0022.5340.33258
Net working capital(4.60)25733135427622.01987
Cash flow
Cash from operations93.60136143(65.10)(3.55)608317
Cash from investing34.00(2.30)(40.30)31.1093.10178(198)
Cash from financing(130)(157)(77.80)22.50(107)(782)(41.05)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue67.1070.3067.3066.4059.5060.7056.1061.40
Revenue growth (YoY)+12.8%+15.8%+20.0%+8.1%+11.8%---
Other income0.100.500.4042.402.4013.002.8019.50
Total expenses55.1064.5055.1054.6049.2049.8046.1055.20
EBITDA12.005.8012.2011.8010.3010.9010.006.20
EBITDA margin+17.9%+8.3%+18.1%+17.8%+17.3%+18.0%+17.8%+10.1%
Depreciation1.401.301.601.601.501.501.501.70
Interest0.900.900.902.503.003.103.303.20
Profit before tax9.804.1010.1050.108.2019.308.0020.80
Tax2.50(53.10)3.5056.502.405.702.7010.30

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue2,2292,2902,1221,9661,9011,9291,8221,752
Revenue growth (YoY)+17.3%+18.7%+16.5%+12.2%+9.8%---
Other income19.9023.7020.509.8012.0011.909.2021.70
EBITDA248326250336290342268275
EBITDA margin+11.2%+14.3%+11.8%+17.1%+15.4%+17.9%+14.8%+15.8%
Depreciation12711712110598.1095.2091.3091.40
Interest54.2056.5056.1050.2049.0052.7055.6061.00
Profit before tax86.4017693.40190154206130144
Tax30.0056.7037.6070.4051.9054.7029.8041.90
Net profit56.4011955.80120102151101102
EPS (₹)3.567.523.527.576.479.686.366.46
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue8,2807,2346,7036,2826,1306,0995,976
Revenue growth+14.5%+7.9%+6.7%+2.5%+0.5%+2.1%-
Other income66.0041692.8050.6011.29291258
Total expenses7,0796,0615,9715,5624,9844,7234,461
Employee cost2,7012,2682,2162,1662,0431,9231,843
EBITDA1,2001,1737327191,1461,3751,515
EBITDA margin+14.5%+16.2%+10.9%+11.5%+18.7%+22.6%+25.4%
Depreciation440369382554382349340
Interest212240272188145184200
Profit before tax61498117027.806301,1331,233
Tax21714497.8092.70217297335
Net profit43640045.30(389)416856922
Net profit margin+5.3%+5.5%+0.7%-6.2%+6.8%+14.0%+15.4%
EPS (₹)25.2253.134.88(3.84)26.0052.5156.39
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital15.8015.8015.8015.9015.9215.9215.93
Reserves & surplus7,0776,2395,4185,3835,3034,7265,588
Shareholders' funds (net worth)7,0936,2555,4345,3995,3194,7415,604
Minority interest2.80(16.30)(12.80)(7.50)(2.16)0.030.00
Secured loans54045649652326540.78999
Unsecured loans3,0742,2753,1683,1532,9272,7893,810
Total debt3,6152,7313,6643,6773,1922,8304,808
Total liabilities13,04810,7629,7489,4318,6127,69210,572
Assets
Gross block10,1677,8237,8697,3686,6926,0907,983
Net block6,9665,1765,0915,1834,8714,6096,340
Capital work in progress4,0403,6302,1031,5621,090897768
Investments61.4043.5042.2025623924169.36
Inventories1,2321,1291,2901,3801,2551,1291,845
Sundry debtors1,0708929169619288201,293
Cash & bank balances1,2681,0899571,0149846711,400
Loans & advances541468714406342332500
Total current assets4,1093,5773,8763,7623,5092,9525,038
Total current liabilities2,2241,8221,5901,4191,0769791,686
Net working capital1,8851,7552,2862,3432,4331,9743,352
Total assets13,04810,7629,7489,4318,6127,69210,572
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,0889561,0149845021,1541,005
Net cash from operating activities1,2271,0729716618381,7841,543
Net cash from investing activities(1,143)512(596)(474)(323)(727)(267)
Net cash from financing activities94.90(1,453)(432)(157)(32.60)(1,709)(1,050)
Net change in cash179132(57.50)30.10482(652)225
Closing cash1,2681,0899571,0149846711,400
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.5%+7.9%+6.7%+2.5%+0.5%+2.1%-
EBITDA growth+2.3%+60.3%+1.7%-37.2%-16.6%-9.2%-
PBT growth-37.4%+475.1%+513.3%-95.6%-44.4%-8.2%+36.5%
Net income growth+9.1%+782.1%+111.6%-193.5%-51.4%-7.1%-
Revenue CAGR (3Y)+9.6%+5.7%+3.2%+1.7%-12.4%-6.7%+0.7%
EBITDA CAGR (3Y)+18.6%+0.8%-19.0%-22.0%-7.7%-3.3%+4.0%
Profitability & leverage
Net income margin+4.8%+11.6%+1.1%-1.0%+6.7%+13.7%+15.0%
Return on capital employed+6.9%+8.4%+6.4%+3.1%+9.5%+11.9%+14.1%
Return on net worth+6.0%+6.8%+0.8%-7.3%+8.2%+16.6%+17.3%
Debt / equity0.480.550.680.640.600.740.93
Long-term debt / equity0.430.490.620.560.540.640.78
Interest cover27.8729.8777.80113.7819.0317.9416.99
Efficiency & per share
Fixed asset turnover0.920.920.880.890.960.870.80
Inventory turnover7.015.985.024.775.144.103.66
Debtors turnover8.448.017.146.657.015.774.66
EPS (₹)25.2253.134.88(3.84)26.0052.5156.39
Dividend per share (₹)5.005.005.005.005.005.005.00
Book value per share (₹)448.91395.88343.92339.58334.10297.85351.78
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue67.1070.3067.3066.4059.5060.7056.1061.40
Revenue growth (YoY)+12.8%+15.8%+20.0%+8.1%+11.8%---
Other income0.100.500.4042.402.4013.002.8019.50
Total expenses55.1064.5055.1054.6049.2049.8046.1055.20
EBITDA12.005.8012.2011.8010.3010.9010.006.20
EBITDA margin+17.9%+8.3%+18.1%+17.8%+17.3%+18.0%+17.8%+10.1%
Depreciation1.401.301.601.601.501.501.501.70
Interest0.900.900.902.503.003.103.303.20
Profit before tax9.804.1010.1050.108.2019.308.0020.80
Tax2.50(53.10)3.5056.502.405.702.7010.30
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2642317858107262,7103,140
Revenue growth+13.9%-70.5%-3.1%+11.6%-73.2%-13.7%-
Other income45.7020.2010313812647.88173
Total expenses2231947688077192,2822,771
Employee cost10492.10190167164221265
EBITDA40.1037.7016.503.106.46427369
EBITDA margin+15.2%+16.3%+2.1%+0.4%+0.9%+15.8%+11.8%
Depreciation6.006.6048.3043.2036.9199.97107
Interest7.3012.9029.9018.5010.99102136
Profit before tax72.5038.4041.7079.3084.72273299
Tax9.3019.2010.1029.404.2358.69(22.30)
Net profit70.8422.2032.3649.6580.47215326
Net profit margin+26.9%+9.6%+4.1%+6.1%+11.1%+7.9%+10.4%
EPS (₹)3.971.211.993.145.0513.4620.16
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital15.9015.9015.9015.9015.9315.9315.93
Reserves & surplus2,2962,3022,3592,3992,4231,2672,591
Shareholders' funds (net worth)2,3122,3182,3742,4142,4391,2822,607
Secured loans50.0021326122295.0095.00899
Unsecured loans2.7012311912387.524091,114
Total debt52.703363803461835042,013
Total liabilities2,3772,6822,7822,7842,6461,7914,687
Assets
Gross block1561,0369979478631492,288
Net block1166997116876371271,865
Capital work in progress11.5019.3037.0047.0035.260.3359.09
Investments2,1761,6571,6571,6571,6461,6461,764
Inventories0.002322513143230.00656
Sundry debtors23.802061941881310.00425
Cash & bank balances10.3012.6036.1011.0022.5340.33258
Loans & advances16.8032.9059.4065.7049.4025.92383
Total current assets50.9048454157952666.251,722
Total current liabilities55.5022721022525044.24735
Net working capital(4.60)25733135427622.01987
Total assets2,3772,6822,7822,7842,6461,7914,687
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12.6036.1011.0022.5040.3535.6418.70
Net cash from operating activities93.60136143(65.10)(3.55)608317
Net cash from investing activities34.00(2.30)(40.30)31.1093.10178(198)
Net cash from financing activities(130)(157)(77.80)22.50(107)(782)(41.05)
Net change in cash(2.30)(23.50)25.10(11.50)(17.82)4.6978.00
Closing cash10.3012.6036.1011.0022.5340.33258
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+13.9%-70.5%-3.1%+11.6%-73.2%-13.7%-
EBITDA growth+6.4%+128.5%+432.3%-52.0%-98.5%+15.7%-
PBT growth+88.8%-7.9%-47.4%-6.4%-69.0%-8.6%+62.9%
Net income growth+219.1%-31.4%-34.8%-38.3%-62.5%-34.2%-
Revenue CAGR (3Y)-31.2%-31.7%-33.8%-36.3%-40.5%-6.4%+8.0%
EBITDA CAGR (3Y)+134.7%+80.0%-66.2%-79.7%-72.8%-7.5%+5.1%
Profitability & leverage
Net income margin+24.0%+8.3%+4.0%+6.2%+11.1%+7.9%+10.2%
Return on capital employed+1.8%+1.9%+2.6%+3.6%+4.3%+11.6%+9.9%
Return on net worth+3.1%+0.8%+1.3%+2.1%+4.3%+11.0%+13.0%
Debt / equity0.080.150.150.110.180.650.75
Long-term debt / equity0.050.100.100.080.160.460.44
Interest cover21.4141.48-94.03-46.13-36.0931.1252.02
Efficiency & per share
Fixed asset turnover0.440.230.810.891.432.221.53
Inventory turnover2.270.962.782.544.498.265.47
Debtors turnover2.291.164.105.0811.1112.746.93
EPS (₹)3.971.211.993.145.0513.4620.16
Dividend per share (₹)5.005.005.005.005.005.005.00
Book value per share (₹)145.43145.79149.34151.86153.1180.51163.67

To see the full year-wise statements and ratios of Jubilant Pharmova Limited, buy the company report.

Board of directors of Jubilant Pharmova Limited

Jubilant Pharmova has 10 current directors and 32 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Priyavrat Bhartia
Also directs: SPB Management Advisors LLP, Ssbpb Advisors LLP, Jubilant Ingrevia Limited and 5 more
Managing Director23 May 20179 Years 4 MonthsCurrent
Arun Seth
Also directs: Jubilant Ingrevia Limited, Trinetra Business Advisors India LLP, Dixon Technologies (India) Limited and 5 more
Director22 Oct 20188 Years 0 MonthsCurrent
Hari Shanker Bhartia
Also directs: Jubilant Ingrevia Limited, Jubilant Foodworks Limited, Jubilant Enpro Private Limited and 5 more
Director01 Nov 198342 Years 11 MonthsCurrent
Arjun Shanker Bhartia
Also directs: Jubilant Enpro Private Limited, Hindustan Coca Cola Holdings Limited, Hindustan Coca Cola Holdings Private Limited and 5 more
Managing Director23 May 20179 Years 4 MonthsCurrent
Shyam Sunder Bhartia
Also directs: SPB Management Advisors LLP, Ssbsb Advisors LLP, Sbssb Advisors LLP and 5 more
Director21 Jun 197848 Years 4 MonthsCurrent
Vivek Mehra
Also directs: Chambal Fertilisers and Chemicals Limited, HT Media Limited, Vivek Mehra LLP and 5 more
Director23 May 20179 Years 4 MonthsCurrent
Showing 6 of 10 current directors. View all directors

Auditor

Jubilant Pharmova Limited is audited by BSR & Co LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
BSR & Co LLPFY 2023101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 47.70%, foreign institutional investors hold 15.90%, domestic institutional investors hold 12.40% and retail and other public shareholders hold 24.00%.

Promoters: 47.70%DII (Domestic Institutional): 12.40%FII (Foreign Institutional): 15.90%Retail & Others: 24.00%
Sep 2026
QUARTER
47.70% Promoters
12.40% DII (Domestic Institutional)
15.90% FII (Foreign Institutional)
24.00% Retail & Others
Promoter holding - history
Now 47.70% · Sep 2026High 47.70% · Dec 2025Low 47.70% · Dec 2025
46%46.8%47.5%48.3%49%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 47.70%Mar 2026: 47.70%Jun 2026: 47.70%Sep 2026: 47.70%47.70%47.70%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters47.70%47.70%47.70%47.70%
Public52.30%52.30%52.30%52.30%

Charges & borrowings

Open charges
₹260 Cr
Satisfied charges
₹9,285.57 Cr
Breakdown by lending institutions
Others₹210.00 Cr
Yes Bank Limited₹50.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
29 Aug 2025101158066Others₹50 CrOpen
28 Aug 2023100776281Others₹100 CrOpen
23 Mar 2023100699047Yes Bank Limited₹50 CrOpen
15 Feb 2023100683612Others₹60 CrOpen
26 Feb 2024100882140Hdfc Bank Limited₹100 CrSatisfied

To see the full charge records of Jubilant Pharmova Limited, buy the company report.

Total charge records: 84 View all charges

Deals & funding

Jubilant Pharmova Limited has 72 deals on record (47 market trades, 17 secondary share transfers, 8 funding rounds), with disclosed funding of ₹498.8 Cr; the latest was in June 2025.

Total deals
72
Market trades
47
Secondary share transfers
17
Funding rounds
8
Disclosed funding
₹498.8 Cr

Deals on record (5 of 72)

WhenDealAmountParties
Jun 2025Market trade₹432.39 CrBuyer: Kotak Mahindra Mutual Fund, Kotak Funds - India Midcap Fund
Seller: Jubilant Enpro Private Limited, Nikita Resources Pvt Ltd
Sep 2024Market trade₹95.58 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Aug 2024Market trade₹81.88 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Aug 2021Market trade₹15.43 CrBuyer: an individual
Seller: Yesha Developers LLP
Mar 2021Secondary share transferUndisclosedBuyer: Shyam Sunder Bhartia Family Trust, Hari Shanker Bhartia Family Trust, Government Pension Fund Global, an individual
Seller: Torino Overseas Pvt, Rance Investment Holdings Ltd, Motilal Oswal Most Focused Multicap 35 Fund

To see the full deal history of Jubilant Pharmova Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Jubilant Pharmova Limited was last rated by Crisil on 10 Nov 2020.

Rating agencyRated onRating
Crisil10 Nov 2020

To see the full credit ratings and regulatory alerts of Jubilant Pharmova Limited, buy the company report.

MSME payment delays

Jubilant Pharmova Limited has 9 MSME Form 1 returns on record between 2022 and 2024, listing 2,102 overdue payments to 260 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 260)

SupplierAmount dueDue sinceReported on
Tirupati Industries
Binary Biological Equipments
an individual supplier
Reliability Engineering Industries Private Limited
Ari Armaturen Steamline LLP

To see the full MSME payment records of Jubilant Pharmova Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Jubilant Pharmova has 7 subsidiary companies. This group structure data is as of FY 2022. The table lists each entity with its relationship and holding.

7
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Jubilant Generics LimitedU24100UP2013FLC060821
Jubilant Biosys LimitedU24110UP1998PLC029591
Jubilant Clinsys LimitedU24232UP2004PLC029008
Jubilant First Trust Healthcare LimitedU74110UP2006PLC035993
Jubilant Draximage LimitedU74900UP2009FLC038194
Jubilant Therapeutics India LimitedU74994UP2019PLC114901

To see the full group structure of Jubilant Pharmova Limited, buy the company report.

Employees & EPFO

Jubilant Pharmova Limited has a workforce of 1,055 employees on its EPFO records as of Mar 30, 2024, across 8 active EPFO establishments.

Employee count
1,055
Active EPFO establishments
8
Employee growth
2.73%

GST

Jubilant Pharmova has 36 GST registrations: 4 active and 32 cancelled or inactive.

Total GSTINs
36
Active
4
Cancelled / inactive
32
GSTINStateStatusRegistered on
09AABCV0200H1ZUUttar PradeshActive01 Jul 2017
09AABCV0200H3ZSUttar PradeshActive14 Jul 2017
27AABCV0200H1ZWMaharashtraActive01 Jul 2017
29AABCV0200H3ZQKarnatakaActive01 May 2022

To see the full GST registrations and return filing status of Jubilant Pharmova Limited, buy the company report.

Recent activity

Jubilant Pharmova Limited has 69 board changes on record since 1978: 40 appointments and 29 cessations. The latest: Arun Kumar Sharma was appointed as CFO on 17 Oct 2025.

Filing
Jubilant Pharmova Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Uttar Pradesh I.
Charges
A charge registered on 26 Feb 2024 via Charge ID 100882140 with Hdfc Bank Limited was fully satisfied on 12 Jan 2026.
Charges
A charge registered on 25 Jul 2022 via Charge ID 100600986 with Axis Bank Limited was fully satisfied on 14 Nov 2025.
Charges
A charge registered on 20 Sep 2022 via Charge ID 100616639 with Others was fully satisfied on 28 Oct 2025.
Appointed
Arun Kumar Sharma was appointed as CFO.
Charges
A charge with Others of Rs. 50.00 Cr registered on 29 Aug 2025 with Charge ID 101158066 was modified on 13 Oct 2025.
Ceased
Arvind Chokhany ceased to be CFO.
Ceased
Ramakrishnan Arul ceased to be Whole-Time Director.
AGM
Jubilant Pharmova Limited last Annual general meeting of members was held on 29 Aug 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 50.00 Cr with Charge ID 101158066 was registered on 29 Aug 2025.
Appointed
Ramakrishnan Arul was appointed as Whole-Time Director.
Ceased
Jinang Pratap Parekh ceased to be Whole-Time Director.

272 earlier events are in the company report.

News

JUBLPHARMA: Rs. 18.28 Crores NSE Block Trade; for ~ 200,560 Shares, at Rs. 911.60
12 Oct 2026 · Exchange Update
Jubilant Pharmova: Board Agrees To Issue Up To ₹800 Crore In Non-Convertible Debentures Through Private Placement; Looking For Member Approval For Up To ₹2,500 Crore In Debt Securities Over The Next Year.
12 Oct 2026 · Exchange Update
Jubilant Pharmova: Company Announces CAD 94.5 Million Investment to Increase Ruby-Fill® Production Capacity; Government of Canada to Provide CAD 23.8 Million in Support; Expansion Targets Growing Demand in Radiopharmaceuticals.
08 Oct 2026 · Exchange Update
Jubilant Pharmova: Weighs Options To Raise Funds By Issuing Non-Convertible Debentures.
07 Oct 2026 · Exchange Update

Frequently asked questions

Jubilant Pharmova is an active public limited company based in Uttar Pradesh, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 21 June 1978 (48+ years old) and is registered under CIN L24116UP1978PLC004624. Listed on BSE: 530019 and NSE: JUBLPHARMA.

Jubilant Pharmova reported revenue of ₹8,279.6 Cr for FY 2025-26 (up 14.4% YoY) based on consolidated financials.

Jubilant Pharmova has 10 current directors:

The latest financial statements of Jubilant Pharmova on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 August 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Jubilant Pharmova is 09AABCV0200H1ZU, registered in Uttar Pradesh. The company has 36 GST registrations in all, of which 4 are active and 32 are cancelled or inactive. Other active GSTINs include 09AABCV0200H3ZS (Uttar Pradesh), 27AABCV0200H1ZW (Maharashtra), 29AABCV0200H3ZQ (Karnataka).

The CIN (Corporate Identification Number) of Jubilant Pharmova is L24116UP1978PLC004624. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Jubilant Pharmova is a listed company as per MCA records. Its shares are listed on both BSE (code: 530019) and NSE (symbol: JUBLPHARMA).

Jubilant Pharmova has 330 court cases on record: 191 filed by the company and 140 filed against it. 58 are pending. Most are in the high courts.

Jubilant Pharmova was incorporated on 21 June 1978, making it 48+ years old. It is registered with the Registrar of Companies, Uttar Pradesh.

Jubilant Pharmova has 72 deals on record (47 market trades, 17 secondary share transfers, 8 funding rounds), with disclosed funding of ₹498.8 Cr; the latest was in June 2025.

Arun Kumar Sharma was appointed as CFO on 17 Oct 2025. Arvind Chokhany ceased to be CFO on 30 Sep 2025. Ramakrishnan Arul ceased to be Whole-Time Director on 31 Aug 2025. Jubilant Pharmova has 69 board changes on record in total.